Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 802,316 | 470,783 | 859,902 | 732,836 | 673,470 |
| Marketable Securities | 1,276,723 | 404,695 | 482,756 | 434,122 | 351,958 |
| Receivables | 464,107 | 423,537 | 417,714 | 399,307 | 408,137 |
| Inventories | 605,492 | 572,239 | 588,911 | 598,989 | 605,156 |
| Other current assets | 28,126 | 10,089 | 12,413 | 13,236 | 26,325 |
| TOTAL | $3,303,421 | $1,990,479 | $2,466,286 | $2,289,093 | $2,175,317 |
| Non-Current Assets | |||||
| PPE Net | 485,743 | 511,639 | 476,648 | 482,001 | 482,712 |
| Investments And Advances | 9,689,284 | 14,387,010 | 16,230,630 | 11,580,390 | 10,503,040 |
| Intangibles | 592,872 | 601,282 | 468,989 | 476,768 | 483,680 |
| Other Non-Current Assets | 302,381 | 308,979 | 310,823 | 289,301 | 288,408 |
| TOTAL | $11,070,280 | $15,808,910 | $17,487,090 | $12,828,460 | $11,757,840 |
| Total Assets | $14,373,700 | $17,799,390 | $19,953,380 | $15,117,560 | $13,933,160 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 504 | 489 | 1,739 | 1,736 | 1,738 |
| Accounts payable and accrued liabilities | 160,651 | 141,941 | 136,398 | 133,457 | 138,494 |
| Accrued Expenses | 184,542 | 276,986 | 243,946 | 208,888 | 174,889 |
| Other current liabilities | 211,586 | 127,936 | 177,721 | 154,942 | 166,462 |
| TOTAL | $648,331 | $680,938 | $649,916 | $587,052 | $609,892 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,196,739 | 10,514 | 10,645 | 10,779 | 10,901 |
| Deferred Revenues | N/A | 50,852 | N/A | N/A | N/A |
| aiOther Non-Current Liabilities | 349,823 | 358,129 | 391,109 | 382,656 | 397,196 |
| TOTAL | $3,542,451 | $3,433,219 | $3,971,086 | $2,935,624 | $2,714,209 |
| Total Liabilities | $4,190,782 | $4,114,157 | $4,621,002 | $3,522,676 | $3,324,101 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,942 | 29,932 | 29,918 | 29,773 | 29,764 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 10,137,630 | 13,525,340 | 15,080,850 | 11,159,470 | 10,245,430 |
| Other shareholders' equity | -308,144 | -175,836 | -62,676 | 124,709 | 68,526 |
| TOTAL | $10,182,920 | $13,685,240 | $15,332,380 | $11,594,880 | $10,609,060 |
| Total Liabilities And Equity | $14,373,702 | $17,799,397 | $19,953,382 | $15,117,556 | $13,933,161 |